In order for our site to display correctly you will need a newer version of your web browser.
The following browsers support numerous web standards including CSS,XHTML, and the DOM (a universal means of controlling the behavior of web pages):
- Netscape v7 or higher (all platforms), Mozilla FireFox (Windows), Camino (Mac OS X), Galeon (Linux GNOME Desktop) or other browser stemming from the Mozilla.org project.
- Opera v7 or higher (Windows, Linux)
- Apple's Safari (Mac OS X)
- Konqueror (Linux KDE Desktop)
- Microsoft Internet Explorer v6 or higher (Windows) or v5 or higher (Macintosh)
Please note that this is not intended be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Finding Cures. Saving Children.
Solid Tumor Program Featured Research
A list of recent featured research from the Solid Tumor team.
St. Jude took another step in the shift from paper to electronic health records August 19 when chemotherapy orders from the Solid Tumor Clinic stopped coming in by fax and began arriving in the pharmacy electronically.
A new combination of anti-cancer drugs, when integrated into an existing treatment for non-Hodgkin lymphoma, causes reduced risk for side effects in children than the conventional regimen.
The drug bevacizumab is widely used to inhibit blood vessel growth in tumors, starving them of oxygen and nutrients. St. Jude researchers have found that the drug also shows promise for attacking neuroblastoma cells themselves.
A new combination of two anti-cancer drugs offers promise in treating recurrent and treatment-resistant bone cancer in children.
Children with bilateral Wilms tumor can retain normal function in both kidneys by undergoing a procedure called bilateral nephron-sparing surgery, even when preoperative scans suggest that the tumors are inoperable.
